Loading...
•
Sep 30
Tmc Q3 2025 Earnings Report
TMC the metals company Inc. reported its third quarter 2025 financial results.
Key Takeaways
TMC the metals company Inc. reported a net loss of $184.5 million and an operating loss of $55.4 million for the third quarter of 2025. The results were significantly impacted by non-cash and non-recurring items, including share-based compensation, fair value changes in royalty and warrant liabilities, and warrant costs. The company ended the quarter with $115.6 million in cash and highlighted progress in its Pre-Feasibility Study and regulatory advancements for deep-sea mineral recovery.
Net loss for Q3 2025 was $184.5 million, primarily due to non-cash and non-recurring items.
Operating loss for the quarter stood at $55.4 million.
Cash and cash equivalents totaled $115.6 million at the end of the quarter.
Net loss per share was $0.46 for Q3 2025.
Tmc
Tmc
Forward Guidance
TMC expects to commence commercial production in the fourth quarter of 2027, contingent on receiving a commercial recovery permit. The company believes its current cash balance will be sufficient to cover working capital and capital expenditure commitments for at least the next twelve months.
Positive Outlook
- Expected commencement of commercial production in Q4 2027, subject to permit.
- Current cash balance of $115.6 million is believed to be sufficient for at least the next twelve months.
- Completion of Pre-Feasibility Study and Initial Assessment with a combined NPV of $23.6 billion.
- Successful production of battery-grade manganese sulfate from nodule-derived product in bench-scale trials.
- NOAA's proposed consolidated application rule under White House review, potentially streamlining permitting.
Challenges Ahead
- Commercial production is contingent on receiving a commercial recovery permit, which is not guaranteed.
- The company's operations are subject to various regulatory and environmental risks.
- Metals price volatility could impact future revenues and profitability.
- Dependence on third parties, including Allseas Group S.A. and PAMCO, for operational success.
- Uncertainties related to processing nodules at a commercial scale.